spacer
home > epc > winter 2001 > the monoclonal anti-idiotype antibody aca 125 - a breakthrough for ovarian cancer
PUBLICATIONS
European Pharmaceutical Contractor

The Monoclonal Anti-Idiotype Antibody ACA 125 - A Breakthrough for Ovarian Cancer

Q About 1.5 per cent of the female population suffer from ovarian
carcinoma - a tumour disease with a high mortality rate - in the
course of their lifetime. It is the fourth most common cause of
death from cancer in women. So why is the prognosis of this
malignant disease so bad?

A Due to the difficulties in making an early diagnosis of ovarian carcinoma, more than 70 per cent of the patients are only diagnosed at advanced stages and almost 20 per cent are already at stage four by the time of diagnosis. Accordingly, the prognosis for these tumours is comparatively poor. Although the prognosis for all stages regarding five-year survival has meanwhile increased, the relative five-year survival rate with advanced tumours is essentially lower. The number of lost years of life adds up to a total of about 100,000 years within the Federal Republic of Germany alone.

Q What approach is taken to the therapy of ovarian carcinoma
depending on the severity, for example a favourable prognosis,
but also rapid progression of large tumour masses and visceral
metastases?

A The aim of primary treatment of ovarian carcinoma is to firstly attain a favourable starting position for further treatment. The prognosis of the disease heavily depends on the post-operative tumour remains from the initial surgical operation. Subsequent treatment by means of chemotherapy - which must be carried out after the operation - is clearly dependent on the result of the surgical operation. Response rates of between 70 and 80 per cent are attained here. However, a smaller number of patients progress relatively quickly into a relapse situation, even after optimal initial therapy that appears to be resistant to chemotherapy and incurable.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer
In Conversation with Dr Uwe Wagner, Deputy Medical Director and Lecturer at the University of Tьbingen's Gynaecological Hospital

Dr Uwe Wagner is Deputy Medical Director and Lecturer at the University of Tьbingen's gynaecological hospital. He is also a member of CellControl's advisory board. Dr Wagner developed the technological platform for the anti-idiotopic antibody ACA 125 and received the Fritz-Acker-Prize 1997 for oncological research into developing ACA 125's highly specific and innovative mechanism of action. In addition, he was awarded the Schmidt-Matthiesen Prize 2000 for gynaecological oncology from the Arbeitsgemeinschaft fьr Gynдkologische Onkologie (AGO) - the German gynaecological oncology society. Dr Wagner has published several scientific articles in international medical publications with a particular focus on immunological issues. He obtained his PhD and MD from the University of Bonn (Germany), and also received his medical and clinical education from the university's gynaecological hospital.


spacer
Dr Uwe Wagner
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

First-in-Human Workshop

7-8 May 2012, Berlin, Germany


More info >>

 
News and Press Releases

Prism Ideas and dMetrics Launch Pioneering Service Analysing Patient–Reported Action, Behaviours and Outcomes with Social Media

Prism Ideas, the multi-national medical marketing and drug development consultants, today announced its collaboration with dMetrics, experts in identifying decisions made by millions of patients online, to launch a pioneering analysis service to evaluate patient healthcare outcomes reported within social media. Combining expertise in language analytics and healthcare, the two companies are interrogating social media to determine patient actions and insights, profiling patient needs, symptoms and response to treatment.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.